vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and RAPT Therapeutics, Inc. (RAPT). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.
ASBP vs RAPT — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-31.4M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -47.7% |
| EPS (diluted) | $-0.04 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.9K | — | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 | ||
| Q4 22 | — | $0 | ||
| Q3 22 | — | $0 | ||
| Q2 22 | — | $886.0K | ||
| Q1 22 | — | $641.0K |
| Q3 25 | $-1.9M | — | ||
| Q3 23 | — | $-31.4M | ||
| Q2 23 | — | $-25.3M | ||
| Q4 22 | — | $-23.0M | ||
| Q3 22 | — | $-21.2M | ||
| Q2 22 | — | $-19.2M | ||
| Q1 22 | — | $-20.5M |
| Q3 25 | 45.5% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | -59015.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -2134.2% | ||
| Q1 22 | — | -3241.3% |
| Q3 25 | -95337.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -2165.2% | ||
| Q1 22 | — | -3193.1% |
| Q3 25 | $-0.04 | — | ||
| Q3 23 | — | $-0.82 | ||
| Q2 23 | — | $-0.66 | ||
| Q4 22 | — | $-0.64 | ||
| Q3 22 | — | $-0.63 | ||
| Q2 22 | — | $-0.62 | ||
| Q1 22 | — | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $184.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $172.8M |
| Total Assets | $2.4M | $199.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q3 23 | — | $184.8M | ||
| Q2 23 | — | $205.0M | ||
| Q4 22 | — | $249.1M | ||
| Q3 22 | — | $195.4M | ||
| Q2 22 | — | $207.3M | ||
| Q1 22 | — | $173.0M |
| Q3 25 | $-11.5M | — | ||
| Q3 23 | — | $172.8M | ||
| Q2 23 | — | $199.7M | ||
| Q4 22 | — | $245.2M | ||
| Q3 22 | — | $189.3M | ||
| Q2 22 | — | $202.1M | ||
| Q1 22 | — | $167.8M |
| Q3 25 | $2.4M | — | ||
| Q3 23 | — | $199.7M | ||
| Q2 23 | — | $220.8M | ||
| Q4 22 | — | $266.2M | ||
| Q3 22 | — | $209.5M | ||
| Q2 22 | — | $222.0M | ||
| Q1 22 | — | $187.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-21.9M |
| Free Cash FlowOCF − Capex | — | $-21.9M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-91.1M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | — | ||
| Q3 23 | — | $-21.9M | ||
| Q2 23 | — | $-28.8M | ||
| Q4 22 | — | $-22.8M | ||
| Q3 22 | — | $-17.1M | ||
| Q2 22 | — | $-15.2M | ||
| Q1 22 | — | $-15.6M |
| Q3 25 | — | — | ||
| Q3 23 | — | $-21.9M | ||
| Q2 23 | — | $-29.0M | ||
| Q4 22 | — | $-22.9M | ||
| Q3 22 | — | $-17.2M | ||
| Q2 22 | — | $-15.8M | ||
| Q1 22 | — | $-15.7M |
| Q3 25 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -1778.9% | ||
| Q1 22 | — | -2453.5% |
| Q3 25 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 63.9% | ||
| Q1 22 | — | 23.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
